Aarti Drugs
Aarti Drugs Limited, commonly referred to as Aarti Drugs, is a prominent player in the pharmaceutical industry, headquartered in Mumbai, India. Established in 1984, the company has made significant strides in the production of active pharmaceutical ingredients (APIs) and formulations, catering to both domestic and international markets. With a diverse portfolio that includes anti-infectives, analgesics, and cardiovascular medications, Aarti Drugs stands out for its commitment to quality and innovation. The company has achieved several milestones, including regulatory approvals from major global health authorities, which solidify its market position. Recognised for its robust manufacturing capabilities and a strong emphasis on research and development, Aarti Drugs continues to contribute to the healthcare sector, ensuring the availability of essential medicines worldwide.
DitchCarbon Score
How does Aarti Drugs's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aarti Drugs's score of 7 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Aarti Drugs's reported carbon emissions
In 2023, Aarti Drugs reported total carbon emissions of approximately 56,820,000 kg CO2e for Scope 1 and about 76,414,000 kg CO2e for Scope 2. This represents a significant reduction from 2022, where emissions were approximately 75,908,000 kg CO2e for Scope 1 and 131,625,000 kg CO2e for Scope 2. The company has shown a consistent downward trend in emissions over the years, with total emissions for Scope 1 and Scope 2 decreasing from about 84,380,000 kg CO2e in 2021 to approximately 134,234,000 kg CO2e in 2023. Aarti Drugs has not publicly disclosed specific reduction targets or climate pledges, indicating a potential area for improvement in their climate commitments. The company’s emissions intensity metrics, which measure emissions relative to revenue and physical output, suggest ongoing efforts to enhance efficiency. For instance, in 2023, the total Scope 1 and Scope 2 emission intensity was reported at 5.333e-06 kg CO2e per rupee of turnover and 3,990 kg CO2e per tonne of product sold. Overall, Aarti Drugs is making progress in reducing its carbon footprint, but further transparency regarding specific climate commitments and targets would strengthen its sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 84,380,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 104,966,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aarti Drugs is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
